Sign In
Buy GKOS
$134.65
+3.46 (+2.64%)
At Close: Jun 23, 2026
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
03:16pm, Friday, 05'th Jun 2026
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Glaukos Announces Participation in Upcoming Investor Conferences
07:00am, Tuesday, 12'th May 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
11:55am, Thursday, 30'th Apr 2026
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
11:21pm, Wednesday, 29'th Apr 2026
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:00pm, Wednesday, 29'th Apr 2026
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare t
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
07:41pm, Wednesday, 29'th Apr 2026
Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.
Glaukos Announces First Quarter 2026 Financial Results
04:05pm, Wednesday, 29'th Apr 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
11:26am, Thursday, 16'th Apr 2026
GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.
Glaukos Announces the Release of its 2025 Sustainability Report
07:00am, Thursday, 16'th Apr 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos Receives Permanent J-code for Epioxa™
04:05pm, Wednesday, 15'th Apr 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29
07:00am, Wednesday, 08'th Apr 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal di
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS
04:43am, Monday, 06'th Apr 2026
Capricorn Fund Managers Ltd bought a new stake in shares of Glaukos Corporation (NYSE: GKOS) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securiti
Reviewing Anteris Technologies Global (NASDAQ:AVR) and Glaukos (NYSE:GKOS)
01:24am, Monday, 06'th Apr 2026
Glaukos (NYSE: GKOS - Get Free Report) and Anteris Technologies Global (NASDAQ: AVR - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two busines
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC
03:10am, Friday, 03'rd Apr 2026
Allspring Global Investments Holdings LLC lifted its position in shares of Glaukos Corporation (NYSE: GKOS) by 32.8% during the undefined quarter, according to its most recent filing with the Securiti
